Krystal Biotech (NASDAQ:KRYS) Stock Rating Reaffirmed by HC Wainwright

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $200.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 13.36% from the company’s current price.

Separately, Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and an average price target of $177.63.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $15.51 during trading on Monday, hitting $176.43. 630,472 shares of the company’s stock traded hands, compared to its average volume of 379,360. The stock has a fifty day moving average of $185.14 and a two-hundred day moving average of $163.82. The firm has a market cap of $5.04 billion, a P/E ratio of 94.30 and a beta of 0.84. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. During the same period in the prior year, the business earned ($1.76) earnings per share. The firm’s quarterly revenue was up 452400.0% compared to the same quarter last year. As a group, analysts expect that Krystal Biotech will post 2 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech in the 2nd quarter valued at about $28,000. GAMMA Investing LLC increased its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares during the period. Key Financial Inc acquired a new position in Krystal Biotech in the second quarter valued at about $28,000. Blue Trust Inc. raised its holdings in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in Krystal Biotech by 11.1% in the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after buying an additional 94 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).